Association between a CYP3A4 Genetic Variant and Clinical Presentation in African-American Prostate Cancer Patients

Pamela L. Paris, Patrick A. Kupelian, Jeffrey M. Hall, Teri L. Williams, Howard Levin, Eric A. Klein, Graham Casey, and John S. Witte

Departments of Cancer Biology [P. L. P., G. C.], Radiation Oncology [P. A. K.], Anatomic Pathology [H. L.], and Urology [E. A. K.], Cleveland Clinic Foundation, Cleveland, Ohio 44195; PPGx, Inc., La Jolla, California 92037 [J. M. H., T. L. W.]; and Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio 44106 [J. S. W.]

Abstract

Prostate cancer incidence, clinical presentation, and mortality rates vary among different ethnic groups. A genetic variant of CYP3A4, a gene involved in the oxidative deactivation of testosterone, has been associated recently with prostate cancer development in Caucasians. To further investigate this variant, we evaluated its genotype frequencies in different ethnic groups and its association with clinical presentation of prostate cancer in African Americans. CYP3A4 genotypes were assayed in healthy male Caucasian (n = 117), Hispanic (n = 121), African-American (n = 116), Chinese (n = 46), and Japanese (n = 34) volunteers using the TaqMan assay. The association between CYP3A4 genotype and prostate cancer presentation was determined in 174 affected African-American men. Genotype frequency of the CYP3A4 variant differed substantially across ethnic groups, with African Americans much more likely to carry one or two copies than any other group (two-sided P < 0.0001). Among African Americans, 46% (80 of 174) of men with prostate cancer were homozygous for the CYP3A4 variant, whereas only 28% (32 of 116) of African-American healthy volunteers were homozygous (two-sided P < 0.005). A consistent positive association was observed between being homozygous for the CYP3A4 variant in African-American prostate cancer patients and clinical characteristics. Men homozygous for the CYP3A4 variant were more likely to present with higher grade and stage of prostate cancer in a recessive model (odds ratio [OR], 1.7; 95% confidence interval [CI], 0.9–3.4). This association was even stronger for men who were >65 years of age at diagnosis (n = 103; OR, 2.4; 95% CI, 1.1–5.4). In summary, the CYP3A4 genotype frequency in different ethnic groups broadly followed trends in prostate cancer incidence, presentation, and mortality in the United States. African-American prostate cancer patients had a higher frequency of being homozygous for the CYP3A4 variant than healthy African-American volunteers who were matched solely based on ethnicity. Among the patients, those who were homozygous for the CYP3A4 variant were more likely to present with clinically more advanced prostate cancer.

Introduction

Prostate cancer is the most common non-skin-related cancer affecting men in the United States and the second leading cause of cancer-related deaths (1). The incidence of prostate cancer varies substantially across ethnic groups, with African-American men exhibiting the highest rates worldwide and Asian men having the lowest rates (2). Furthermore, African-American men generally present with more severe forms of prostate cancer, potentially leading to a more aggressive course of the disease (3, 4). Unfortunately, the etiology of prostate cancer remains unclear, with little known about molecular markers that may help distinguish between an indolent versus an aggressive clinical course. The identification of genetic or molecular risk factors for prostate cancer susceptibility and aggressiveness, including those that distinguish ethnic differences, is an important goal.

Testosterone plays a critical role in stimulating prostate cell division. CYP3A4, a protein belonging to the cytochrome P-450 supergene family, is involved in the metabolism and most likely the deactivation of testosterone (5, 6). A germ-line genetic variant in the 5′ regulatory region of the CYP3A4 gene (A to G transition at position –293 from the ATG start site) has been reported recently and was found to be associated with a higher clinical grade and stage in Caucasian men with prostate cancer, especially among those diagnosed at a later age with no family history of the disease (7). Therefore, we examined the genotype frequencies of the CYP3A4 variant in different ethnic groups and determined that the variant was much more common in African Americans. This motivated us to undertake a study of African Americans that had been diagnosed with prostate cancer to evaluate whether the presence of the CYP3A4 variant was associated with clinical characteristics (Gleason grade, PSA3 and TNM stage) that play a role in the clinical course of this disease.

Materials and Methods

Subjects. To determine the CYP3A4 genotype frequencies across ethnic groups, a convenience sample of 117 Caucasian,
121 Hispanic, 116 African-American, 46 Chinese, and 34 Japanese healthy male volunteers from the Southern California area were enrolled in the study. A blood sample was collected from each subject who self reported ethnicity and medical status following signed consent. A sample of 205 African-American men diagnosed with prostate cancer between years 1993 and 1998 at the Cleveland Clinic Foundation were identified through the Cleveland Clinic Foundation’s Familial Cancer Registry. Of the 205 tissue samples for which tissue blocks or slides were available, 174 yielded DNA of sufficient quality for PCR amplification and were included in the study. All prostate cancer samples were either biopsies at the time of diagnosis or resections at the time of surgery. The study design was approved by the Institutional Review Board of the Cleveland Clinic Clinical. Clinical characteristics, including Gleason grade, PSA, and TNM stage, as well as other potentially important factors, such as age at diagnosis and family history of prostate cancer, were obtained from medical records. Family history, a question that was routinely asked as part of an office visit, was defined as having at least one first-degree relative with prostate cancer. Tumor grade was determined according to the Gleason system (8). The tumor stage was determined after review of the microscopic sections of the specimen (9). Among prostate cancer patients, the mean age at diagnosis was 66 years, with a range of 43–91 years.

DNA Extraction. For healthy volunteers, DNA was extracted from blood using a kit from Gentra Systems, Inc. (Plymouth, Minnesota). For prostate cancer cases, DNA was extracted from sectioned paraffin-embedded tissue blocks (10–12 µm sections) or pathology slides. Paraffin was removed after treatment with xylene. DNA was then extracted using the QiAamp Tissue Kit (Qiagen, Valencia, CA). The final elution was in 50 or 100 µl Tris (pH 9) buffer for slides or sections, respectively.

**CYP3A4 Variant Detection by the TaqMan Assay.** The CYP3A4 genotype was determined using the TaqMan assay (10). Samples were assayed in triplicate in a Robbins 96-well plate. The primers for CYP3A4 were derived from published sequence (11). A 126-bp fragment was amplified by PCR in reactions containing 20 ng of genomic DNA, 900 nM forward sequence (11). A 126-bp fragment was amplified by PCR in CYP3A4 (10). Samples were assayed in triplicate in a Robbins 96-well Variant Detection by the TaqMan Assay. CYP3A4 Tris (pH 9) buffer for slides or sections, respectively. (Qiagen, Valencia, CA). The final elution was in 50 or 100 µl PCR reaction using the inner nested primers in the CYP3A4 assay. The control DNAs included one homozygous wild-type (AA), one heterozygous (AG), and one homozygous (GG) variant sample (confirmed by DNA sequencing).

A randomly selected homozygous variant sample (concluded from the TaqMan assay) was sequenced directly. Sequencing was carried out by the Molecular Biotechnology Core within the Lerner Research Institute using an ABI 377 DNA Sequencer (ABI, Foster City, CA). The sample was shown to carry the expected nucleotide change, an A to G transition in the CYP3A4 gene.

**Statistical Methods.** CYP3A4 genotype frequencies were calculated within each ethnic group and among the men with prostate cancer, using data obtained with the TaqMan assay. To compare these observed frequencies with their expected values across ethnic groups and between African-American volunteers and prostate cancer patients, Pearson χ² test statistics were calculated. All corresponding Ps were two-sided. The frequencies, χ² tests, and Ps were all calculated using the GAUSS programming language (Aptech Systems, Inc., Maple Valley, WA).

For the comparison of clinical characteristics in the African-American cases, ORs were calculated to estimate the relative risks that carriers of CYP3A4 variants present with more aggressive clinical characteristics. The CYP3A4 genotypes with one or two variants were investigated individually (i.e., AG versus AA, GG versus AA) and in combinations that reflected recessive (GG versus AG and AA combined) and dominant (GG and AG combined versus AA) models. Categories of clinical characteristics were defined a priori as follows: Gleason grade, two groups (cut point, 7); PSA at diagnosis, two groups (cut point, 10 ng/ml); TNM stage, two groups (T 1a–c, T 2a–b versus T 2c, T 3, or metastatic). Following Rebeck et al. (7), a constellation of grade and stage characteristics was defined as low (Gleason grade ≤7 and tumor stage T 1a–c, T 2a–b) and high (Gleason grade >7 or tumor stage T 2c, T 3, or metastatic). ORs and 95% CIs were calculated using logistic regression (SAS Institute, Inc., Cary, NC). These models included age at diagnosis (continuous variable) and family history (defined as the existence of any first-degree relative with prostate cancer) as potential confounders. The possible effect modification by these factors was also evaluated [per Rebeck et al. (7)] by undertaking analyses of the data stratified by age at diagnosis (cut point, 65 years). This latter analysis still included age at diagnosis (continuous) and family history as potential confounders. Additional stratification by family history was also performed. Finally, three subjects had some missing values because of incomplete medical records (i.e., one was missing PSA, one TNM stage, and one PSA and TNM stage) and were excluded from the corresponding analyses.

BSA, 0.25 mM each deoxynucleotide triphosphate, 0.015 unit AmpliTaq Gold per 20-µl PCR reaction, and 10–15 µl of eluted DNA (concentration unknown). Touchdown thermocycle conditions were used: 95°C for 10 min; 3-cycle PCR 94°C for 30 s, 66°C for 30 s, 72°C for 30 s decreasing 1°C per cycle for 16 cycles; then 3-cycle PCR 94°C for 30 s, 50°C for 30 s, 72°C for 30 s for 22 cycles; 72°C for 4 min; 4°C hold.

Concentrations of various dilutions of the resultant PCR products containing pico green were measured on a CytoFluor II spectrophotometer against a standard curve of known concentrations of human placental DNA. Five ng of DNA were used for each PCR reaction using the inner nested primers in the TaqMan assay described above. Genomic DNAs containing known CYP3A4 genotypes were processed in the same manner as controls for the assay. The control DNAs included one homozygous wild-type (AA), one heterozygous (AG), and one homozygous (GG) variant sample (confirmed by DNA sequencing).
Results

**CYP3A4 Frequencies among Ethnic Groups.** Genotype frequencies of the CYP3A4 variant across ethnic groups are shown in Table 1. The G variant was not found in the Chinese or Japanese populations. At least one copy of the variant was identified in 7% (8 of 117) and 20% (24 of 121) of the Caucasian and Hispanic populations, respectively. In contrast, 81% (94 of 116) of the African-American population carried at least one variant allele, and 28% (32 of 116) were GG homozygotes. Comparing the genotype frequency in African Americans to that in the other ethnic groups gave two-sided Ps < 0.0001 for each comparison. During the review process, a relevant on-line paper was brought to our attention. In examining three ethnic groups, Walker et al. (12) estimated the allele frequency of the CYP3A4 variant to be 0.53 in African Americans, 0.09 in Caucasians, and 0 in Taiwanese. This is consistent with the trend that we found in African-American, Caucasian, and Asian populations.

**Association of CYP3A4 Genotype and Prostate Cancer.** Among African Americans with prostate cancer, 83% (144 of 174) carried at least one copy of the variant allele. Thirty-seven % (64 of 174) of those with a variant were heterozygotes, whereas 46% (80 of 174) were homozygous (Table 1). Comparing the CYP3A4 genotypes between these men and the African-American healthy volunteers gave a two-sided P = 0.005. Comparing the homozygous (GG) versus the AA and AG combined gave a two-sided P = 0.002 between these two groups.

Stratification of the CYP3A4 genotypes and clinical characteristics in the 174 African Americans with prostate cancer are shown in data columns 1–3 in Table 2. Fifty-five % (16 of 29) of the men presenting with a Gleason grade >7 were homozygous for the variant, whereas only 44% (64 of 145) presenting with a lower Gleason grade were homozygous for the variant. A similar difference was observed for the grade/stage variable. Forty-nine % of the men homozygous for the CYP3A4 variant presented with PSA >10, whereas only 41% with PSA ≤10 were homozygous. There was no difference in genotype by TNM stage.

The fourth column of Table 2 shows ORs comparing GG to AG and AA combined (reflecting a recessive model). In this case, being homozygous for the CYP3A4 variant appeared to increase the risk of presenting with high grade/stage (OR, 1.7; 95% CI, 0.9–3.1). Slightly weaker associations were observed for Gleason grade (OR, 1.6) and PSA at diagnosis (OR, 1.6). When comparing GG and AG to AA (reflecting a dominant model), we found similar, albeit modest, positive associations. In particular, for high Gleason grade, the OR was 2.1 (95% CI, 0.6–7.4), whereas for high grade/stage and PSA, the OR was 1.4 (95% CI, 0.5–3.5 and 0.6–3.4, respectively). A comparison of men with AG to AA and GG to AA showed a slight increasing trend for Gleason grade, where the adjusted ORs were 1.7 and 2.4, respectively. For PSA at diagnosis and grade/stage, there were only positive associations for the comparison of GG to AA, where ORs were 1.8 and 1.7, respectively. The 95% CIs for these associations were, however, quite wide, reflecting the small number of subjects with some genotype/clinical characteristic combinations.

Data restricted to men over the age of 65 are shown in Table 3. In this group, ~10–20% more men presented with more severe clinical characteristics if they were homozygous for the variant. Looking at the recessive model, having two copies of the CYP3A4 variant was associated with presenting with higher Gleason grade and PSA at diagnosis (OR, 2.2; column 4 of Table 3). As above, however, the CIs for both of these associations were somewhat wide (lower bounds, 0.9 and 0.8, respectively). We observed a stronger association for grade/stage (OR, 2.4; 95% CI, 1.1–5.4). The dominant model (i.e., GG and AG versus AA) and a comparison of AG to AA and GG to AA gave relatively weaker results (not shown). Additional stratification by family history did not show stronger results.

**Discussion**

In this study, we show that the frequency of a germ-line CYP3A4 variant is substantially higher among African-American men than among other ethnic groups, and that African-American men with prostate cancer have a significantly higher frequency of being homozygous for the CYP3A4 variant than healthy African Americans. We report consistent positive associations between the CYP3A4 variant and clinical characteristics in African-American men with prostate cancer. The strongest association was between homozygous variant carriers and high Gleason grade and grade/stage when restricted to men >65 years. This finding is in agreement with a recent study reporting on the association between the CYP3A4 variant and prostate cancer in a Caucasian population (7). Therefore, the CYP3A4 variant may represent an important prognostic factor for prostate cancer occurrence and aggressiveness among not only Caucasians but also African Americans. However, these data should be verified in a larger population. In addition, differences in the frequency of the variant between ethnic groups might help to explain some of the interethnic differences in the incidence, presentation, and mortality of this disease.

The CYP3A4 variant reported is an A to G alteration that occurs in the nifedipine-specific element in the 5’ regulatory region of the CYP3A4 gene. This element may be required for expression of the CYP3A4 gene (11). The CYP3A4 protein oxidizes testosterone, which might also deactivate the hormone, although this has yet to be proven (5, 6). As a result, men carrying the CYP3A4 variant allele may have more testosterone available to be converted to dihydrotestosterone, which is the main male sex hormone that regulates prostate cell division (13). Consequently, there exists a biological rationale for the CYP3A4 variant playing a role in prostate cancer development and aggressiveness. Metabolism of testosterone may no longer be efficiently processed in men carrying the CYP3A4 variant.
CYP3A4 Polymorphism and Prostate Cancer

The substantial difference in CYP3A4 variant genotype frequencies among the ethnic groups evaluated here is intriguing with regards to the potential involvement of this variant in prostate cancer development. Asians, who have the lowest rates of prostate cancer, were found not to carry the CYP3A4 variant. Some Hispanics and Caucasians, who have prostate cancer incidence rates between Asians and African Americans, carried the variant at a much lower frequency than the African-American group. These data are consistent with findings reported previously (12). Therefore, the frequency of the CYP3A4 variant broadly parallels previously reported (2) incidence rates across ethnic groups in the United States.

There are a number of limitations to this study: (a) our comparison of genotype frequencies between African-American prostate cancer patients and healthy volunteers only supports ecological-level inferences. Although appearing healthy at the time of blood collection, some of the volunteers may develop prostate cancer later in life. Nevertheless, we would expect this potential misclassification to be nondifferential and thus lead to an underestimate of our observed differences in CYP3A4 genotype frequencies between prostate cancer patients and healthy volunteers (16). A recent study, however, observed a similar allele frequency (0.53) in the CYP3A4 variant among African Americans from Pennsylvania (12), as observed in our California African Americans (0.54). This suggests that any potential differences in racial admixture between California and Pennsylvania African Americans did not alter CYP3A4 frequencies, and by geographic extrapolation, that there may not be such differences between California and Ohio. If the variant

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>CYP3A4 genotype, n (%)a</th>
<th>OR (95% CI)b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AG</td>
</tr>
<tr>
<td><strong>Gleason grade</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤7</td>
<td>27 (19%)</td>
<td>54 (37%)</td>
</tr>
<tr>
<td>&gt;7</td>
<td>3 (10%)</td>
<td>10 (34%)</td>
</tr>
<tr>
<td><strong>PSA at diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤10</td>
<td>13 (20%)</td>
<td>25 (39%)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>16 (15%)</td>
<td>39 (36%)</td>
</tr>
<tr>
<td><strong>TNM stage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1a–c/T2a–b</td>
<td>24 (17%)</td>
<td>51 (37%)</td>
</tr>
<tr>
<td>T2c/T3/T4/M</td>
<td>6 (17%)</td>
<td>13 (37%)</td>
</tr>
<tr>
<td>Grade/Stagec</td>
<td>Low</td>
<td>23 (19%)</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>7 (14%)</td>
</tr>
</tbody>
</table>

* n, number of subjects. A, wild type; G, variant.
*b Comparing those with GG versus those with AA and AG genotypes (recessive model). Adjusted for age at diagnosis and family history.
*c Units for PSA, ng/ml.
*d Combined Gleason grade and TNM stage is defined as: Low, T1a–T1c or T2a–b stage and Gleason grade ≤7; High, T2c, T3, T4, or M stage and Gleason grade >7. Gleason grading is detailed in Gleason (8) and TNM staging in Spiessl (9).

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>CTP3A4 genotype, n (%)a</th>
<th>OR (95% CI)b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AG</td>
</tr>
<tr>
<td><strong>Gleason grade</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤7</td>
<td>15 (19%)</td>
<td>35 (44%)</td>
</tr>
<tr>
<td>&gt;7</td>
<td>3 (13%)</td>
<td>7 (30%)</td>
</tr>
<tr>
<td><strong>PSA at diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤10</td>
<td>6 (24%)</td>
<td>12 (48%)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>11 (14%)</td>
<td>30 (39%)</td>
</tr>
<tr>
<td><strong>TNM stage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1a–c/T2a–b</td>
<td>12 (16%)</td>
<td>33 (45%)</td>
</tr>
<tr>
<td>T2c/T3/T4/M</td>
<td>6 (21%)</td>
<td>9 (31%)</td>
</tr>
<tr>
<td>Grade/Stagec</td>
<td>Low</td>
<td>11 (17%)</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>7 (17%)</td>
</tr>
</tbody>
</table>

* n, number of subjects. A, wild type; G, variant.
*b Comparing those with GG versus those with AA and AG genotypes (recessive model). Adjusted for age at diagnosis and family history.
*c Units for PSA, ng/ml.
*d Combined Gleason grade and TNM stage is defined as: Low, T1a–T1c or T2a–b stage and Gleason grade ≤7; High, T2c, T3, T4, or M stage and Gleason grade >7. Gleason grading is detailed in Gleason (8) and TNM staging in Spiessl (9).
is associated with prostate cancer incidence and/or survival, then it will be important to establish the allele frequencies across age groups in future studies. However, a carefully conducted case-control study will resolve these issues; (b) the associations observed in our evaluation of prostate cancer clinical characteristics were consistent but because of sample size limitations, some had broad 95% CIs. Although these associations were modest, the high frequency of the CYP3A4 variant and the increased incidence and mortality of prostate cancer among African Americans suggest an association between disease and the presence of the variant, particularly in homozygous carriers; (c) we could only compare a moderate range of clinical characteristics because most subjects in this study presented with clinically localized disease, which did not allow for a full analysis of the impact of the CYP3A4 variant on prostate cancer aggressiveness; and (d) the consequences of carrying a particular CYP3A4 genotype may differ depending on the disease or outcome being investigated. In fact, possession of the wild-type genotype has been associated recently with an increased risk for treatment-related (chemotherapy) leukemia (17).

In summary, African Americans have a higher incidence of prostate cancer and appear to present with more advanced stage disease at time of diagnosis (3, 4). The data that we present on African-American prostate cancer patients, along with other recent work (7), imply that carriers of the CYP3A4 variant are more susceptible to the development of more aggressive forms of this disease. If the association reported here is supported by further research and should prove to be indeed causal, early genetic screening for the CYP3A4 variant may be warranted, and postdiagnostic screening could prove useful in choosing the most appropriate course of treatment. However, it should be recognized that prostate cancer is a complex disease; therefore, this gene may only play a small part in its etiology.

References


Association between a CYP3A4 Genetic Variant and Clinical Presentation in African-American Prostate Cancer Patients


Cancer Epidemiol Biomarkers Prev 1999;8:901-905.

Updated version  Access the most recent version of this article at: http://cebp.aacrjournals.org/content/8/10/901

Cited articles  This article cites 12 articles, 3 of which you can access for free at: http://cebp.aacrjournals.org/content/8/10/901.full#ref-list-1

Citing articles  This article has been cited by 18 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/8/10/901.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/8/10/901. Click on “Request Permissions” which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.